Cancer “vaccine” injected directly into tumors works in mice
Full article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997264/
Immunotherapy is treatment that uses the immune system to fight cancer. Still in its infancy, it is a promising therapy that is changing how certain cancers are treated. A new study reports that tumors in lab mice were eliminated when they were injected with two immune system-enhancing agents. This new approach is called in situ (at the original site) vaccination because the injections are given directly into the tumors. It worked on several different types of mouse tumors, including lymphomas and breast tumors. This approach may be safer than conventional immunotherapy because it uses very low doses of the agents and it does not require tumors to have particular markers. (02/23/18)
Questions To Ask Your Health Care Provider
- Is immunotherapy an option for me at this time?
- Are there any harmful side effects from vaccines, or from immunotherapy in general?
- Do I qualify for any immunotherapy clinical trials?
Open Clinical Trials
- NCT03789097: Vaccination With Flt3L, Radiation, and Poly-ICLC. This is a combination of 4 therapies, three of which are used to treat a single "target site" of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into the blood stream (intravenous or "IV").
- NCT02643303: A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers. This is an open-label, multicenter Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in people with advanced, measurable, biopsy-accessible cancers.
- NCT03831295: SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies. This trial studies the effects of injection of SD-101 and BMS-986178 into tumors for treating patients with metastatic cancers.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.